4 stories mentioning ATRUpdated 13d ago
Every FINWIRES story that references ATR, newest first.
Marc Prieur, Segment President, on June 09, 2026, sold 5,000 shares in Aptargroup (ATR) for $577,895. Following the Form 4 filing with the SEC, Prieur has control over a total of 19,323 common shares of the company, with 19,323 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/896622/000089662226000139/xslF345X05/form4.xml
Xiangwei Gong, President, Asia, on May 26, 2026, sold 4,200 shares in Aptargroup (ATR) for $487,765. Following the Form 4 filing with the SEC, Gong has control over a total of 11,416 common shares of the company, with 10,774 shares held directly and 642 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/896622/000089662226000132/xslF345X05/form4.xmlPrice: $115.38, Change: $-1.00, Percent Change: -0.86%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain our 12-month target at $149, 26.8x our 2026 EPS estimate, a premium to its three-year average forward P/E of 26.5x. We trim our 2026 EPS view by $0.12 to $5.56 and decrease our 2027 EPS by $0.15 to $6.40. The injectables division continues to validate our thesis, with 20% Y/Y growth in Q1 as management actively works to increase capacity so the division can expand further. We note that emergency medicine faces a $65M headwind in 1H 2026 as it destocks from prior inventory, which led to flat Q1 core sales and weaker gross margins. Management is confident its pharma growth will expand beyond GLP-1 to both systemic nasal drug delivery and pulmonary biologics. Margin weakness and an unfavorable mix in the Beauty segment are temporary, with normal margins returning in 2H 2026 in our view. We continue to believe ATR is poised to capture significant growth in the biologics markets. ATR could face higher raw material costs as supply chains become stretched due to uncertainty in the Middle East.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ATR delivered mixed Q1 2026 results with revenue growth of 11% to $983M (+$27M vs. consensus) but flat core sales, while adjusted EPS declined 8% to $1.19 (+$0.04 vs. consensus). EBITDA margins compressed 150 bps to 19.2%, marking the second consecutive quarter of margin decline due to emergency medicine destocking, unfavorable product mix, and operational challenges. The quarter's results underscore growing operational challenges that are now overshadowing ATR's defensive growth characteristics and end-market positioning. Q2 2026 EPS guidance of $1.32-$1.40 suggests sequential improvement and management expects emergency medicine destocking to moderate. ATR announced Gael Touya as next CEO effective September 1, 2026, and returned $131M to shareholders with 1.4x leverage. Two consecutive quarters of margin compression and flat core sales represent notable deterioration from previously consistent profitability improvement.
